NCW visits TCS Nashik: What the fact-finding committee will examine and why its report matters beyond this case
Read More Pharma Industry News Corcept Therapeutics (NASDAQ: CORT) puts resistant hypertension in the cortisol spotlight with new MOMENTUM trial data Corcept Therapeutics says 27.3% of resistant hypertension patients may have hypercortisolism. Read what the MOMENTUM data could mean next. byPallavi MadhirajuMarch 29, 2026